Roche has stopped a pair of phase 3 Alzheimer’s disease trials after an interim analysis found they were unlikely to hit their primary endpoint. The setback wipes out near-term hopes of getting the AC ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Credit: Getty Images. The designation was supported by initial interim safety and immunogenicity data from the phase 1b/2 ABATE trial. The Food and Drug Administration (FDA) has granted Fast Track ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A new protein which will help scientists to understand why nerve cells die in people with Alzheimer's disease has been designed in a University of Sussex laboratory. In people with Alzheimer's, ...
The beta amyloid peptide (Abeta) is the primary component of the senile plaques observed in the brains of Alzheimer's patients, and this peptide is toxic to neurons and other cells in many different ...
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 ...
South Korean neuroscientists and bioengineers have successfully developed a new blood test for Alzheimer's disease (AD), which was shown to be capable of rapidly distinguishing between AD patients and ...
A new test may help scientists answer a perplexing “which came first” question about the development of Alzheimer’s disease, possibly pointing the way to earlier diagnosis or even treatment. Subscribe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results